(IN BRIEF) EssilorLuxottica showcased an integrated scientific ecosystem spanning the full eye care continuum at ARVO 2026. The company combined capabilities from Heidelberg Engineering, RetinAI, and Espansione to demonstrate how advanced imaging, AI-powered analytics, diagnostics, and therapeutic technologies can support … Read the full press release
Posted in Apparel, Fashion & Beauty, Artificial Intelligence (AI), Business, France, Management, Marketing, News, Technology
Tagged AI diagnostics, artificial intelligence, ARVO 2026, clinical research, diabetic retinopathy, digital ophthalmology, espansione, Essilor Stellest, EssilorLuxottica, EssilorLuxottica Expands Vision Science and Medical Technology Integration Through ARVO Showcase, EssilorLuxottica Presents Integrated AI-Driven Eye Care Ecosystem at ARVO 2026, Ettore Mosca, eye care innovation, eye-light platform, healthcare technology, Heidelberg Engineering, Leonardo learning ecosystem, Medical Technologies, multimodal imaging, myopia management, Norbert Gorny, OCT imaging, Olga Prenat, ophthalmic research, ophthalmology, photobiomodulation, RetinAI, retinal imaging, retinal therapy, vision care, vision science
(IN BRIEF) The European Commission has approved Ranluspec, a ranibizumab biosimilar developed by Lupin and commercialized by Sandoz, for the treatment of neovascular age-related macular degeneration and several other retinal disorders. The therapy has demonstrated comparable efficacy and safety to … Read the full press release
Posted in Business, European Union, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged access to medicines, Afqlir, Basel Switzerland, biosimilars Europe, choroidal neovascularization, diabetic macular edema, diabetic retinopathy, EU commercialization rights, European Commission approval, eye disease treatment, Lucentis reference medicine, lupin, neovascular age-related macular degeneration, ophthalmology treatments, pharmaceutical partnership, ranibizumab biosimilar, Ranluspec, retinal vein occlusion, Sandoz, Sandoz and Lupin Advance European Market Entry for Ranluspec Following Regulatory Clearance, Sandoz Secures European Approval for Ranluspec to Expand Access to Biosimilar Treatment in Retinal Diseases
(IN BRIEF) Boehringer Ingelheim has entered into a global collaboration and licensing agreement with Palatin Technologies to develop melanocortin receptor agonists as a new treatment for retinal diseases, beginning with diabetic retinopathy and diabetic macular edema. The approach targets inflammation, … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged biopharmaceutical collaboration, Boehringer Ingelheim, Carl Spana, diabetic macular edema, diabetic retinopathy, eye health innovation, inflammation, licensing agreement, melanocortin receptor agonists, neurodegeneration, Palatin Technologies, parttnership, Remko Bakker, Retinal Disease Treatment, vascular dysfunction, Vision Preservation, €280 million milestone payments
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?